Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 3/20 | 0.39 |
| ▸ | CCND1 | P24385 | 3/20 | 0.39 |
| ▸ | CCND3 | P30281 | 3/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CCNH | P51946 | 1/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20956319 | 0.84 | EIF2AK4 (0.37) | CDK4CCND1CCND3CDK6TRPV1 | |
| SCHEMBL20956374 | 0.81 | CCND3 (0.54) | CDK4CCND1CCND3CDK6TRPV1 | |
| SCHEMBL20956346 | 0.81 | CDK4 (0.35) | CDK4CCND1CCND3CDK6TRPV1 | |
| SCHEMBL20956336 | 0.78 | CDK4 (0.58) | CDK4CCND1CCND3CDK6IDH1 | |
| SCHEMBL22390600 | 0.76 | TP53 (0.33) | TRPV1TP53MDM2 | |
| SCHEMBL20956353 | 0.75 | CDK4 (0.50) | CDK4CCND1CCND3CDK6TRPV1 | |
| SCHEMBL19402045 | 0.73 | CDK4 (0.48) | CDK4CCND1CCND3CDK6TRPV1 | |
| SCHEMBL14846570 | 0.71 | IDH1 (0.56) | IDH1 | |
| SCHEMBL20956371 | 0.70 | TRPV1 (0.41) | TRPV1 | |
| SCHEMBL20956322 | 0.67 | CCNT1 (0.52) | CDK4CCND1CCND3CDK6TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | G1 THERAPEUTICS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | MKI67, TYMS, TYMP | CDK4 40/4885CCND1 63/4885CCND3 169/4885 |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | MKI67, TYMS, TYMP | CDK4 40/4885CCND1 63/4885CCND3 169/4885 |
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | MKI67, TYMS, TYMP | CDK4 40/4885CCND1 63/4885CCND3 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.